FORX-002

FORX-002 is a preclinical small molecule anticancer drug candidate developed by FoRx Therapeutics. The compound is part of a pipeline focused on targeting DNA replication stress pathways, which are emerging as promising targets in oncology. While the precise molecular target and mechanism of action for FORX-002 have not been publicly disclosed, FoRx Therapeutics specializes in developing first-in-class compounds that interfere with key molecular processes involved in cancer cell proliferation and survival, particularly those related to DNA replication stress[2][9]. As of the latest available information, FORX-002 remains at the discovery stage and has not yet entered clinical trials[9].